Abstract MP163: Renal Sympathetic Denervation (RDN) Improves Exercise Performance and Vascular Function in the Setting of Cardiometabolic HFpEF

Hunter Hidalgo,Juan Gao,Zhen Li,Thomas E Sharp,Huijing Xia,Daniel R Kapusta,Traci T Goodchild,David J Lefer
DOI: https://doi.org/10.1161/res.127.suppl_1.mp163
IF: 23.213
2020-07-31
Circulation Research
Abstract:Background: Heart failure with preserved ejection fraction (HFpEF) has emerged as a subclass of heart failure for which there are no effective treatments. HFpEF is induced in a large number of patients by central obesity, metabolic syndrome, and sustained activation of the sympathetic nervous system (SNS). Methods: We examined the effects of RDN in a clinically relevant model of HFpEF. The ZSF1-Obese rat exhibits the key components of cardiometabolic HFpEF including hypertension and diabetes. At 20 wks of age, ZSF1-Obese rats underwent bilateral radiofrequency RDN (RF-RDN) or sham RF-RDN and were followed for 6 weeks. LV function, blood pressure, LVEDP, vascular function, myocardial fibrosis, metabolic profiling, and exercise capacity were evaluated. We also assessed mitochondrial function of cardiac and skeletal muscle. Results: RF-RDN resulted in significant improvements in LV diastolic function, vascular relaxation, and exercise capacity. Significant reductions in blood pressure and LVEDP were observed following RF-RDN treatment. RF-RDN ameliorated cardiac fibrosis while improving cardiac and skeletal muscle mitochondrial function. We did not observe any effects of RF-RDN on the metabolic status of the ZSF-1 rat. Conclusion: Our data suggest that RF-RDN is a viable treatment option for cardiometabolic HFpEF through halting renal SNS hyperactivation and enhancing mitochondrial function to exert beneficial effects on the heart and circulation.
cardiac & cardiovascular systems,peripheral vascular disease,hematology
What problem does this paper attempt to address?